Prognostic impact of tumor size reduction ...
Document type :
Compte-rendu et recension critique d'ouvrage
PMID :
Title :
Prognostic impact of tumor size reduction assessed by magnetic resonance imaging after radiochemotherapy in patients with locally advanced cervical cancer.
Author(s) :
Cordoba, A. [Auteur]
Durand, B. [Auteur]
Escande, Alexandre [Auteur]
Faculté de Médecine Henri Warembourg - Université de Lille
Taieb, Sophie [Auteur]
Amor, M. B. H. [Auteur]
Le Deley, Marie Cécile [Auteur]
Service de Biostatistiques [CHRU Lille]
Michel, A. [Auteur]
Service de Biostatistiques [CHRU Lille]
Le Tinier, Florence [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hudry, Delphine [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM]
Martinez, C. [Auteur]
Leblanc, Eric [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM]
Becourt, S. [Auteur]
Abdedaim, C. [Auteur]
Bresson, L. [Auteur]
Lartigau, Eric [Auteur]
Centre de Recherche en Informatique, Signal et Automatique de Lille - UMR 9189 [CRIStAL]
Mirabel, Xavier [Auteur]
Service d'oncologie médicale (CHRU Lille)
Narducci, Fabrice [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM]
Durand, B. [Auteur]
Escande, Alexandre [Auteur]
Faculté de Médecine Henri Warembourg - Université de Lille
Taieb, Sophie [Auteur]
Amor, M. B. H. [Auteur]
Le Deley, Marie Cécile [Auteur]
Service de Biostatistiques [CHRU Lille]
Michel, A. [Auteur]
Service de Biostatistiques [CHRU Lille]
Le Tinier, Florence [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hudry, Delphine [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM]
Martinez, C. [Auteur]
Leblanc, Eric [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM]
Becourt, S. [Auteur]
Abdedaim, C. [Auteur]
Bresson, L. [Auteur]
Lartigau, Eric [Auteur]
Centre de Recherche en Informatique, Signal et Automatique de Lille - UMR 9189 [CRIStAL]
Mirabel, Xavier [Auteur]
Service d'oncologie médicale (CHRU Lille)
Narducci, Fabrice [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM]
Journal title :
FRONTIERS IN ONCOLOGY
Pages :
1046087
Publisher :
Frontiers Media
Publication date :
2022-12-20
ISSN :
2234-943X
English keyword(s) :
locally advanced cervical cancer
tumor shrinkage
MRI
radiochemotherapy
brachytherapy
tumor shrinkage
MRI
radiochemotherapy
brachytherapy
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Objective: Pelvic magnetic resonance imaging (MRI) is a key exam used for the initial assessment of loco-regional involvement of cervical cancer. In patients with locally advanced cervical cancer, MRI is used to evaluate ...
Show more >Objective: Pelvic magnetic resonance imaging (MRI) is a key exam used for the initial assessment of loco-regional involvement of cervical cancer. In patients with locally advanced cervical cancer, MRI is used to evaluate the early response to radiochemotherapy before image-guided brachytherapy, the prognostic impact of which we aimed to study.Methods: Patients with locally advanced cervical cancer treated using concomitant radiochemotherapy followed by closure treatment between January 2010 and December 2015 were included in this study. Clinical, anatomopathological, radiological, therapeutic, and follow-up data were evaluated.Results: After applying the inclusion and exclusion criteria to the initially chosen 310 patients, 232 were included for evaluation (median follow-up period, 5.3 years). The median age was 50 years (range, 25–83 years), and the median tumor size was 47.5 mm (range, 0–105 mm). Based on the International Federation of Gynaecology and Obstetrics classification system, 9 patients were in stage IB2; 20, IB3; 2, IIA; 63, IIB; 4, IIIA; 7, IIIB; and 127, IIIC1 or higher. The re-evaluation MRI was performed at the median dose of 55.5 Gy, and median reduction in tumor size was 55.2% (range, −20–100%). There was a difference between the disease-free and overall survival rates of the patients with a tumor response greater or lesser than 50%. The risk of recurrence or death reduced by 39% in patients with a tumor size reduction >50%. The overall 5-year survival rate of patients with a response greater and lesser than 50% were 77.7% and 61.5%, respectively. The 5-year disease-free survival rate for these two groups of patients were 68.8% and 51.5%, respectively.Conclusion: Our study confirms the prognostic impact of tumor size reduction using MRI data obtained after radiochemotherapy in patients with locally advanced cervical cancer.Show less >
Show more >Objective: Pelvic magnetic resonance imaging (MRI) is a key exam used for the initial assessment of loco-regional involvement of cervical cancer. In patients with locally advanced cervical cancer, MRI is used to evaluate the early response to radiochemotherapy before image-guided brachytherapy, the prognostic impact of which we aimed to study.Methods: Patients with locally advanced cervical cancer treated using concomitant radiochemotherapy followed by closure treatment between January 2010 and December 2015 were included in this study. Clinical, anatomopathological, radiological, therapeutic, and follow-up data were evaluated.Results: After applying the inclusion and exclusion criteria to the initially chosen 310 patients, 232 were included for evaluation (median follow-up period, 5.3 years). The median age was 50 years (range, 25–83 years), and the median tumor size was 47.5 mm (range, 0–105 mm). Based on the International Federation of Gynaecology and Obstetrics classification system, 9 patients were in stage IB2; 20, IB3; 2, IIA; 63, IIB; 4, IIIA; 7, IIIB; and 127, IIIC1 or higher. The re-evaluation MRI was performed at the median dose of 55.5 Gy, and median reduction in tumor size was 55.2% (range, −20–100%). There was a difference between the disease-free and overall survival rates of the patients with a tumor response greater or lesser than 50%. The risk of recurrence or death reduced by 39% in patients with a tumor size reduction >50%. The overall 5-year survival rate of patients with a response greater and lesser than 50% were 77.7% and 61.5%, respectively. The 5-year disease-free survival rate for these two groups of patients were 68.8% and 51.5%, respectively.Conclusion: Our study confirms the prognostic impact of tumor size reduction using MRI data obtained after radiochemotherapy in patients with locally advanced cervical cancer.Show less >
Language :
Français
Popular science :
Non
Collections :
Source :
Files
- document
- Open access
- Access the document
- fonc-12-1046087.pdf
- Open access
- Access the document
- document
- Open access
- Access the document
- fonc-12-1046087.pdf
- Open access
- Access the document